661 related articles for article (PubMed ID: 27760868)
1. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
Neurology; 2016 Nov; 87(20):2074-2081. PubMed ID: 27760868
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study.
Yamout BI; El-Ayoubi NK; Nicolas J; El Kouzi Y; Khoury SJ; Zeineddine MM
J Immunol Res; 2018; 2018():9084759. PubMed ID: 30539030
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
[TBL] [Abstract][Full Text] [Related]
5. A retrospective observational study of rituximab treatment in multiple sclerosis patients in Cyprus.
Leonidou E; Pantzaris M; Kleopa KA; Loizidou MA; Kyriakides T; Christou YP
Postgrad Med; 2019 Sep; 131(7):486-489. PubMed ID: 31353999
[No Abstract] [Full Text] [Related]
6. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review.
Castillo-Trivino T; Braithwaite D; Bacchetti P; Waubant E
PLoS One; 2013; 8(7):e66308. PubMed ID: 23843952
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in multiple sclerosis at general hospital level.
Hellgren J; Risedal A; Källén K
Acta Neurol Scand; 2020 Jun; 141(6):491-499. PubMed ID: 31990978
[TBL] [Abstract][Full Text] [Related]
8. Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
Zecca C; Bovis F; Novi G; Capobianco M; Lanzillo R; Frau J; Repice AM; Hakiki B; Realmuto S; Bonavita S; Curti E; Brambilla L; Mataluni G; Cavalla P; Di Sapio A; Signoriello E; Barone S; Maniscalco GT; Maietta I; Maraffi I; Boffa G; Malucchi S; Nozzolillo A; Coghe G; Mechi C; Salemi G; Gallo A; Sacco R; Cellerino M; Malentacchi M; De Angelis M; Lorefice L; Magnani E; Prestipino E; Sperli F; Brescia Morra V; Fenu G; Barilaro A; Abbadessa G; Signori A; Granella F; Amato MP; Uccelli A; Gobbi C; Sormani MP
Mult Scler; 2020 Oct; 26(12):1519-1531. PubMed ID: 31573386
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the efficacy and safety of Zytux
Naser Moghadasi A; Darki A; Masoumi P; Hashemi SN; Ghadiri F
Mult Scler Relat Disord; 2019 Nov; 36():101419. PubMed ID: 31586800
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of repeated low-dose rituximab therapy in relapsing-remitting multiple sclerosis: A retrospective case series study.
Zhao D; Zhao C; Lu J; Han Y; Sun T; Ren K; Ma C; Zhang C; Li H; Guo J
Mult Scler Relat Disord; 2023 Feb; 70():104518. PubMed ID: 36657326
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study.
Alcalá C; Gascón F; Pérez-Miralles F; Gil-Perotín S; Navarré A; Boscá I; Coret F; Casanova B
J Neurol; 2018 Jul; 265(7):1690-1697. PubMed ID: 29785523
[TBL] [Abstract][Full Text] [Related]
12. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.
de Flon P; Gunnarsson M; Laurell K; Söderström L; Birgander R; Lindqvist T; Krauss W; Dring A; Bergman J; Sundström P; Svenningsson A
Neurology; 2016 Jul; 87(2):141-7. PubMed ID: 27316241
[TBL] [Abstract][Full Text] [Related]
13. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
Coban H; Germaine S; Dimaandal I; Haberli N; Padam C; Creed MA; Imitola J
Mult Scler Relat Disord; 2021 Aug; 53():103021. PubMed ID: 34077828
[TBL] [Abstract][Full Text] [Related]
14. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population.
Fernandez-Diaz E; Perez-Vicente JA; Villaverde-Gonzalez R; Berenguer-Ruiz L; Candeliere Merlicco A; Martinez-Navarro ML; Gracia Gil J; Romero-Sanchez CM; Alfaro-Saez A; Diaz I; Gimenez-Martinez J; Mendez-Miralles MA; Millan-Pascual J; Jimenez-Pancho J; Mola S; Sempere AP
Ann Clin Transl Neurol; 2021 Feb; 8(2):385-394. PubMed ID: 33369288
[TBL] [Abstract][Full Text] [Related]
15. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.
Tian X; Chen C; Ma L; Wei R; Li M; Wang X; Wu Y; Zhou Y; Cui Y
J Neuroimmunol; 2020 Oct; 347():577317. PubMed ID: 32731048
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Rituximab: Experience of a Single Multiple Sclerosis Center.
Alldredge B; Jordan A; Imitola J; Racke MK
Clin Neuropharmacol; 2018; 41(2):56-59. PubMed ID: 29389745
[TBL] [Abstract][Full Text] [Related]
18. Effect of Rituximab on Expanded Disability Status Scale and Relapse Rate in Multiple Sclerosis Patients.
Mazdeh M; Khamseh M; Taheri M; Ghafouri-Fard S
J Mol Neurosci; 2020 Aug; 70(8):1165-1168. PubMed ID: 32144724
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis.
Boremalm M; Juto A; Axelsson M; Novakova L; Frisell T; Svenningsson A; Lycke J; Piehl F; Salzer J
Eur J Neurol; 2019 Aug; 26(8):1060-1067. PubMed ID: 30762259
[TBL] [Abstract][Full Text] [Related]
20. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]